November 23, 2016 - By Ruchi Gupta · 0 Comments
The stock of Aeterna Zentaris Incorporated (NASDAQ:AEZS) registered an increase of 26.79% in short interest. AEZS’s total short interest was 800,300 shares in November as published by FINRA. Its up 26.79% from 631,200 shares, reported previously. With 688,900 shares average volume, it will take short sellers 1 days to cover their AEZS’s short positions. The short interest to Aeterna Zentaris Incorporated’s float is 8.09%. About 60,201 shares traded hands. AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) has declined 15.23% since April 21, 2016 and is downtrending. It has underperformed by 20.56% the S&P500.
Aeterna Zentaris Inc. is a specialty biopharmaceutical firm engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The company has a market cap of $40.15 million. The Firm operates through the biopharmaceutical segment. It currently has negative earnings. The Firm is engaged in drug development activities and in the promotion of products for others.
Out of 3 analysts covering Aeterna Zentaris Inc. (NASDAQ:AEZS), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Aeterna Zentaris Inc. has been the topic of 5 analyst reports since August 18, 2015 according to StockzIntelligence Inc. The rating was maintained by H.C. Wainwright on Wednesday, December 2 with “Buy”. The stock of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) has “Buy” rating given on Monday, November 9 by Canaccord Genuity. The firm has “Buy” rating by Maxim Group given on Monday, November 23. As per Tuesday, November 24, the company rating was maintained by H.C. Wainwright.
Aeterna Zentaris Inc., incorporated on October 12, 1990, is a specialty biopharmaceutical firm engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Firm operates through the biopharmaceutical segment. The Firm is engaged in drug development activities and in the promotion of products for others. The Company’s principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Firm focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company’s direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Ruchi Gupta